Ratings by Morgan Stanley (Terrance Flynn)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/5/2026 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2026 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/28/2026 | Johnson & Johnson | JNJ | Upgrade | Overweight (Equalweight) |
221.49 (240.40) |
8.54% | Details | |
| 1/22/2026 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/9/2026 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/12/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2025 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2025 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/29/2025 | United Therapeutics | NTHR | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/15/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/1/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/10/2025 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/30/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2025 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/16/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/14/2025 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2025 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/13/2025 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/16/2024 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/3/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2024 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/18/2024 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2024 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/26/2024 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/17/2024 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2024 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/9/2024 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/20/2024 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/5/2024 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2024 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/24/2024 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2023 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/30/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/18/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 8/31/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/9/2023 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2023 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/28/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2023 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2023 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/10/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/5/2023 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/16/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2023 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/13/2023 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/10/2023 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/1/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/4/2022 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/2/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/28/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/19/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 10/12/2022 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/12/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/14/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/14/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/7/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2022 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/8/2022 | Organon & Co. | OGN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/8/2022 | Merck | MRK | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/8/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/8/2022 | Johnson & Johnson | JNJ | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/8/2022 | Abbvie | ABBV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/6/2022 | Pfizer | PFE | New Coverage | Equalweight (N/A) |
51.24 (27.05) |
-47.21% | Details |
